The expansion of the Phase 2 trial for stenoparib indicates progress in Allarity's drug development pipeline, which could lead to positive investor sentiment and potential stock price increase. The focus on optimizing dosing and refining patient selection criteria suggests a strategic approach to enhance clinical outcomes, which is crucial for FDA approval.